Can the Grana Padano and Parmigiano Reggiano production process guarantee a reduction in pathogenic microorganisms equivalent to the pasteurization process?

格拉纳帕达诺干酪和帕尔玛干酪的生产过程能否保证像巴氏杀菌法一样减少致病微生物?

阅读:1

Abstract

Italian hard cheeses made in the Pianura Padana area, such as Grana Padano and Parmigiano Reggiano, are traditionally produced from raw milk and undergo extended ripening periods. These processes generate multiple microbiological hurdles that can inactivate pathogens. However, current European regulations do not formally recognize the impact of these hurdles as equivalent to pasteurization, limiting trade opportunities. This extensive literature review evaluated experimental studies published between 2000 and 2025 assessing pathogen reduction during Grana-type cheese production. Seven studies met the inclusion criteria and examined Escherichia coli, O157:H7 Listeria monocytogenes, Salmonella Typhimurium, Staphylococcus aureus, Mycobacterium bovis, M. avium subsp. paratuberculosis (MAP), and avian influenza viruses (H1N1, H5N1). Across trials, high inoculum levels declined by >4 log10 within 24-48 hours, primarily during curd cooking and acidification. MAP and M. bovis were eliminated during ripening, within 90 days, while both influenza viruses were inactivated within 30 days. Calculated F-values were used as comparative indicators of equivalence, allowing the overall reduction achieved through the production process to be compared with the standard pasteurization benchmark (72°C for 15 seconds). F-values exceeded this high-temperature short-time reference, confirming the substantial lethality of the process. Overall, evidence indicates that traditional Grana-type cheese production ensures microbiological safety at least comparable to pasteurization through the synergistic action of multiple hurdles. While European regulations currently treat ripening as an additional measure rather than an equivalent to pasteurization, our findings support reconsideration of this approach and provide a scientific basis for future regulatory evaluation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。